SHR-A1811 Shows Initial Antitumor Activity, Tolerability in HER2+ Breast Cancer
SHR-A1811 monotherapy demonstrated high clinical activity and was well tolerated in patients with HER2-positive breast cancer.
Related Articles
Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia
Iopofosine I 131 demonstrated durable efficacy and tolerability in heavily pretreated relapsed/refractory Waldenström macroglobulinemia.
Dr Buchbinder on the Potential Role for RP1 Plus Nivolumab in Melanoma After PD-1 Progression
Elizabeth Buchbinder, MD, discusses the implications of the FDA’s decision to grant breakthrough therapy designation to RP1 plus nivolumab in melanoma.
Dr Garmezy on the Rationale for Developing Zelenectide Pevedotin in Urothelial Cancer
Benjamin Garmezy, MD, discusses the rationale for developing zelenectide pevedotin in metastatic urothelial carcinoma.
Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma
Cilta-cel without induction therapy in high-risk smoldering myeloma marked the first study of CAR T-cell therapy in a precursor cancer setting.
Momelotinib Shows Real-World Improvements in Anemia, Symptoms, and Spleen Response in Myelofibrosis
Real-world treatment with momelotinib led to high transfusion independence rates among patients with JAK inhibitor–exposed and –naive myelofibrosis.
Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD
Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.
Landmark Clinical Trial Shows Value of Immunotherapy for… : Oncology Times
An abstract is unavailable.
Zanidatamab Proves Efficacious in Pretreated Biliary Tract Cancer With Potential to Move to the Frontline
James J. Harding, MD, details the significance of the approval of zanidatamab and how the agent could fill unmet needs in biliary tract cancers.
Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML
Select safety measures have improved the prevention and management of risks associated with ponatinib in ALL and CML over 10 years.